OMTX705 + Pembrolizumab + OMTX705 + OMTX705 + OMTX705 + Tislelizumab (BGB-A317) + OMTX705
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Oct 20, 2022 → Dec 1, 2027
NCT ID
NCT05547321About OMTX705 + Pembrolizumab + OMTX705 + OMTX705 + OMTX705 + Tislelizumab (BGB-A317) + OMTX705
OMTX705 + Pembrolizumab + OMTX705 + OMTX705 + OMTX705 + Tislelizumab (BGB-A317) + OMTX705 is a phase 1 stage product being developed by Certara for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05547321. Target conditions include Advanced Solid Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05547321 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor